(Press-News.org) A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.
KS is a cancer that is associated with infection with a herpes virus called HHV-8 and is prevalent in HIV patients. Effective antiretroviral drugs have decreased the incidence of KS, but the cancer eventually progresses in many patients and treatment options are limited.
A carbohydrate-binding protein called galectin-1 is released by a variety of tumors and promotes their growth and metastasis. A group of researchers at the University of Buenos Aires in Argentina now finds that blocking galectin-1 in mice bearing established Kaposi sarcomas slowed tumor growth in part by suppressing the formation of blood vessels that feed the tumor.
If the same holds true in humans, drugs targeting galectin-1 could provide new treatment options for patients with KS. These drugs might also hold promise for other diseases characterized by aberrant blood vessel growth, including macular degeneration and cardiovascular diseases.
###
About The Journal of Experimental Medicine (JEM)
JEM is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jem.org.
Croci, D.O., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111665
Contact information:
Gabriel Rabinovich
University of Buenos Aires
Email: gabriel.r@ibyme.conicet.gov.ar
Sugar-free approach to treating Kaposi sarcoma
2012-10-01
ELSE PRESS RELEASES FROM THIS DATE:
Moderate alcohol consumption may increase risk of atrial fibrillation in people with heart disease
2012-10-01
Moderate alcohol consumption increases the risk of atrial fibrillation in older people with heart disease or advanced diabetes, found a study in CMAJ (Canadian Medical Association Journal).
"Moderate to high alcohol intake was associated with an increased incidence of atrial fibrillation among people aged 55 or older with cardiovascular disease or diabetes," writes Dr. Koon Teo, McMaster University, Hamilton, Ontario, with coauthors. "Among moderate drinkers, the effect of binge drinking on the risk of atrial fibrillation was similar to that of habitual heavy drinking."
The ...
Poor sleep in adolescents may increase risk of heart disease
2012-10-01
Adolescents who sleep poorly may be at risk of cardiovascular disease in later life, according to a study in CMAJ (Canadian Medical Association Journal).
"We found an association between sleep disturbance and cardiovascular risk in adolescents, as determined by high cholesterol levels, increased BMI [body mass index] and hypertension," writes lead author Dr. Indra Narang, respirologist and director of sleep medicine at The Hospital for Sick Children (SickKids), Toronto, Ontario, with coauthors. "These findings are important, given that sleep disturbance is highly prevalent ...
National study finds reduced glaucoma risk in patients who take statins
2012-10-01
SAN FRANCISCO – October 1, 2012 – People who take statins to reduce their risk of cardiovascular disease are less likely to be diagnosed with the most common form of glaucoma, according to a nationwide study of more than 300,000 patients. A University of Michigan School of Medicine research team, directed by Joshua Stein, MD, MS, found that the risk for glaucoma was reduced by eight percent in patients who took statins continuously for two years, compared with patients who did not take statins. The study, the largest to date on the topic, is published in the October issue ...
Overweight teens get mental health boost from even small amounts of exercise
2012-10-01
OTTAWA, Canada – October 1, 2012 – Being obese at any age is commonly associated with a litany of health issues, ranging from diabetes and chronic fatigue to heart complications. Overweight adolescents are also at an increased risk of body dissatisfaction, social alienation and low self esteem, which is why Dr. Gary Goldfield, registered psychologist, clinical researcher at the Children's Hospital of Eastern Ontario (CHEO) Research Institute, and Associate Professor in the Department of Pediatrics, University of Ottawa, set out to discover how exercise might impact these ...
Genetics Society of America's GENETICS journal highlights for October 2012
2012-10-01
Bethesda, MD—October 1, 2012 – Listed below are the selected highlights for the October 2012 issue of the Genetics Society of America's journal, GENETICS. The October issue is available online at www.genetics.org/content/current. Please credit GENETICS, Vol. 192, October 2012, Copyright © 2012.
Please feel free to forward to colleagues who may be interested in these articles.
ISSUE HIGHLIGHTS
Energy-dependent modulation of glucagon-like signaling in Drosophila via the AMP-activated protein kinase, pp. 457
Jason T. Braco, Emily L. Gillespie, Gregory E. Alberto, ...
Evolutionary analysis improves ability to predict the spread of flu
2012-10-01
BETHESDA, MD – October 1, 2012 – With flu season around the corner, getting a seasonal vaccine might be one of the best ways to prevent people from getting sick. These vaccines only work, however, if their developers have accurately predicted which strains of the virus are likely to be active in the coming season because vaccines must be developed in advance of the upcoming flu season. Recently, a team of scientists from Germany and the United Kingdom have improved the prediction methods used to determine which strains of the flu virus to include in the current season's ...
First large scale trial of whole-genome cancer testing for clinical decision-making reported
2012-10-01
VIENNA, Austria, 1 October 2012 – For the first time, researchers have conducted a large trial in which they tested the entire genome of individual breast cancers to help personalize treatment. They released their findings at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
In recent years, a number of drugs have been developed that target specific genetic alterations in cancer. To choose which of these drugs are suitable for individual patients, some genetic testing is performed. "In most of these cases, these genetic testing approaches ...
New findings on optimal duration of trastuzumab therapy for women with HER2+ early breast cancer
2012-10-01
VIENNA, Austria, 1 October 2012 – New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
"These long awaited results constitute a further milestone in the treatment of patients with early breast cancer over-expressing HER2/neu, corresponding to a population of about 12-15% of all cases of breast cancer," commented Prof Christoph Zielinski, Chairman of the Clinical Division of Oncology, at Medical University ...
Phase III data in treatment of renal cell carcinoma reported
2012-10-01
Vienna, Austria, 1 October 2012 – New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney.
Prof Maria De Santis from Kaiser Franz Josef-Spital, Vienna, Chair of the ESMO 2012 Genitourinary program track (who was not involved in the studies) commented: "At this year's ESMO congress, three urgently awaited ...
New findings highlight the challenges of managing blood clotting in cancer patients
2012-10-01
VIENNA, Austria, 1 October 2012 – New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, comments Dr. Fausto Roila, from Medical Oncology Department, Terni, Italy, Chair of the ESMO 2012 Supportive Care Track. "When asymptomatic patients are considered, these events affect ...